G01N 2333/5428
Il-10
G01N2333/5428 (Il-10) appears on 61 US grants and 151 published applications in this corpus.
Search patents in G01N- Granted patents
- 61
- Published applications
- 151
- Assignees
- 122
- Inventors
- 336
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 2 |
| 2009 | 0 | 2 |
| 2010 | 0 | 1 |
| 2011 | 2 | 4 |
| 2012 | 0 | 7 |
| 2013 | 3 | 6 |
| 2014 | 3 | 4 |
| 2015 | 1 | 10 |
| 2016 | 2 | 16 |
| 2017 | 6 | 6 |
| 2018 | 9 | 12 |
| 2019 | 6 | 9 |
| 2020 | 4 | 10 |
| 2021 | 3 | 6 |
| 2022 | 4 | 16 |
| 2023 | 3 | 7 |
| 2024 | 3 | 11 |
| 2025 | 7 | 9 |
| 2026 | 4 | 12 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders30 Jun 2026US 12,667,572 B2Schrödinger, Inc.
- Uses of IL-40 and methods for detecting IL-40 activity31 Mar 2026US 12,590,973 B2Biolegend, Inc.
- Method for diagnosing and treating fibromyalgia24 Feb 2026US 12,560,614 B2Center for Immunology Science
- Methods of detecting and treating cerebral aneurysms17 Feb 2026US 12,553,904 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Controlling a pathogen's resistance to immune surveillance4 Nov 2025US 12,458,670 B2Immune Macro-Biotic Technology UK Limited
- Multi-Analyte Rapid Diagnostic Test for Sepsis Using Novel Biomarkers and Quantum Dot Technology1 Oct 2026US 2026/0298921 A1Trimar Domestic Inc.
- Il-10 receptor antibodies and methods of use thereof13 Aug 2026US 2026/0234240 A1
- Uses of il-40 and methods for detecting il-40 activity6 Aug 2026US 2026/0227413 A1Biolegend, Inc.
- Method for the detection of cancer16 Jul 2026US 2026/0202420 A1Belgian Volition SPRL
- Biomarkers in ex vivo lung perfusion (evlp) perfusate9 Jul 2026US 2026/0194536 A1University Health Network
Most cited
By later US patents
- Process for the measurement of the potency of glatiramer acetate30US 7,429,374 B2Teva Pharmaceutical Industries Ltd. · 2008
- Process for the measurement of the potency of glatiramer acetate28US 7,923,215 B2Teva Pharmaceutical Industries Ltd. · 2011
- Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis19US 8,759,302 B2Teva Pharmaceutical Industries Ltd. · 2014
- Process for the measurement of the potency of glatiramer acetate18US 8,389,228 B2Teva Pharmaceutical Industries Ltd. · 2013
- Assay for detection of IL-10 antibodies11US 8,383,350 B1Merck Sharp & Dohme Corp. · 2013